nach oben

Erschienen in:

06.04.2016

MR-imaging features of hepatocellular carcinoma capsule appearance in cirrhotic liver: comparison of gadoxetic acid and gadobenate dimeglumine

verfasst von: Marco Dioguardi Burgio, Dario Picone, Giuseppe Cabibbo, Massimo Midiri, Roberto Lagalla, Giuseppe Brancatelli

Erschienen in: Abdominal Radiology | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of the study is to compare the MR-imaging features of hepatocellular carcinoma (HCC) capsule appearance on gadoxetic acid and gadobenate dimeglumine-enhanced MR imaging, using imaging-based presumptive diagnosis of HCC as the reference standard.

Methods

Gadoxetic acid and gadobenate dimeglumine-enhanced MR imaging of 51 patients with 71 HCCs were retrospectively reviewed. Three readers graded in consensus, using a five-point scale, the presence (score 4–5) of capsule appearance on images obtained during T1-weighted GRE portal venous phase (PVP), 3-min phase, and hepatobiliary phase (HBP). The Fisher's exact test and the t student unpaired test were performed.

Results

A hyperintense capsule appearance was present either on PVP or 3-min phase in 11/46 and in 24/25 HCCs imaged with gadoxetic acid and gadobenate dimeglumine-enhanced MR imaging, respectively (24% vs. 96% p < 0.001). A hypointense capsule appearance was present on HBP in 8/46 and 0/22 HCCs evaluated with gadoxetic acid and gadobenate dimeglumine-enhanced MR imaging, respectively (17% vs. 0% p = 0.046). A capsule appearance was detected either on PVP, 3-min phase, or HBP in 17/46 (37%) HCCs after gadoxetic acid injection and in 24/25 (96%) HCCs after gadobenate dimeglumine injection (p < 0.001).

Conclusions

A capsule appearance was more frequently seen on gadobenate dimeglumine-enhanced MR imaging when compared to gadoxetic acid-enhanced MR imaging.

Tanimoto A, Kuwatsuru R, Kadoya M, et al. (1999) Evaluation of gadobenate dimeglumine in hepatocellular carcinoma: results from phase II and phase III clinical trials in Japan. J Magn Reson Imaging 10(3):450–460CrossRefPubMed

Hamm B, Staks T, Muhler A, et al. (1995) Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195(3):785–792CrossRefPubMed

Vogl TJ, Kummel S, Hammerstingl R, et al. (1996) Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 200(1):59–67CrossRefPubMed

Nakamura Y, Toyota N, Date S, et al. (2011) Clinical significance of the transitional phase at gadoxetate disodium-enhanced hepatic MRI for the diagnosis of hepatocellular carcinoma: preliminary results. J Comput Assist Tomogr 35(6):723–727CrossRefPubMed

Parkin DM (2001) Global cancer statistics in the year 2000. Lancet Oncol 2(9):533–543CrossRefPubMed

Khan AS, Hussain HK, Johnson TD, et al. (2010) Value of delayed hypointensity and delayed enhancing rim in magnetic resonance imaging diagnosis of small hepatocellular carcinoma in the cirrhotic liver. J Magn Reson Imaging 32(2):360–366. doi:10.1002/jmri.22271 CrossRefPubMed

Rimola J, Forner A, Tremosini S, et al. (2012) Non-invasive diagnosis of hepatocellular carcinoma </= 2 cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. J Hepatol. 56(6):1317–1323. doi:10.1016/j.jhep.2012.01.004 CrossRefPubMed

Vogl TJ, Stupavsky A, Pegios W, et al. (1997) Hepatocellular carcinoma: evaluation with dynamic and static gadobenate dimeglumine-enhanced MR imaging and histopathologic correlation. Radiology 205(3):721–728CrossRefPubMed

Husarik DB, Gupta RT, Ringe KI, Boll DT, Merkle EM (2011) Contrast enhanced liver MRI in patients with primary sclerosing cholangitis: inverse appearance of focal confluent fibrosis on delayed phase MR images with hepatocyte specific versus extracellular gadolinium based contrast agents. Acad Radiol 18(12):1549–1554CrossRefPubMed

10.

Gupta RT, Iseman CM, Leyendecker JR, et al. (2012) Diagnosis of focal nodular hyperplasia with MRI: multicenter retrospective study comparing gadobenate dimeglumine to gadoxetate disodium. AJR Am J Roentgenol 199(1):35–43CrossRefPubMed

11.

Karam AR, Shankar S, Surapaneni P, Kim YH, Hussain S (2010) Focal nodular hyperplasia: central scar enhancement pattern using Gadoxetate Disodium. J Magn Reson Imaging 32(2):341–344CrossRefPubMed

12.

Organ Procurement and Transplantation Network. OPTN/UNOS policy 9.3.G.iv. Organ Procurement and Transplantation Network website. http://optn.transplant.hrsa.gov/ContentDocuments/OPTN_Policies.pdf-nameddest=Policy_09. Published January 1, 2015. Accessed March 16, 2016.

13.

American College of Radiology. Liver Imaging Reporting and Data System, version 2013.1. http://www.acr.org/Quality-Safety/Resources/LIRADS/. Accessed March 16, 2016.

14.

Miraglia R, Pietrosi G, Maruzzelli L, et al. (2007) Predictive factors of tumor response to trans-catheter treatment in cirrhotic patients with hepatocellular carcinoma: a multivariate analysis of pre-treatment findings. World J Gastroenterol 13(45):6022–6026CrossRefPubMedPubMedCentral

15.

Ng IO, Lai EC, Ng MM, Fan ST (1992) Tumor encapsulation in hepatocellular carcinoma. A pathologic study of 189 cases. Cancer 70(1):45–49CrossRefPubMed

16.

Kim MJ, Rhee HJ, Jeong HT (2012) Hyperintense lesions on gadoxetate disodium-enhanced hepatobiliary phase imaging. AJR Am J Roentgenol 199(5):W575–W586CrossRefPubMed

17.

Suh YJ, Kim MJ, Choi JY, et al. (2011) Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI. AJR Am J Roentgenol 197(1):W44–W52. doi:10.2214/AJR.10.5845 CrossRefPubMed

18.

Bashir MR, Huang R, Mayes N, et al. (2015) Concordance of hypervascular liver nodule characterization between the organ procurement and transplant network and liver imaging reporting and data system classifications. J Magn Reson Imaging 42(2):305–314CrossRefPubMed

19.

Forner A, Vilana R, Ayuso C, et al. (2008) Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47(1):97–104. doi:10.1002/hep.21966 CrossRefPubMed

20.

Joo I, Lee JM, Lee DH, et al. (2015) Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout? Eur Radiol 25(10):2859–2868. doi:10.1007/s00330-015-3686-3 CrossRefPubMed

21.

Ishigami K, Yoshimitsu K, Nishihara Y, et al. (2009) Hepatocellular carcinoma with a pseudocapsule on gadolinium-enhanced MR images: correlation with histopathologic findings. Radiology 250(2):435–443. doi:10.1148/radiol.2501071702 CrossRefPubMed

22.

Grazioli L, Olivetti L, Fugazzola C, et al. (1999) The pseudocapsule in hepatocellular carcinoma: correlation between dynamic MR imaging and pathology. Eur Radiol 9(1):62–67CrossRefPubMed

23.

Choi JW, Lee JM, Kim SJ, et al. (2013) Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images and their value as an imaging biomarker. Radiology 267(3):776–786CrossRefPubMed

24.

Kitao A, Zen Y, Matsui O, et al. (2010) Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR imaging-correlation with molecular transporters and histopathologic features. Radiology 256(3):817–826CrossRefPubMed

25.

Fujita N, Nishie A, Kubo Y, et al. (2015) Hepatocellular carcinoma: clinical significance of signal heterogeneity in the hepatobiliary phase of gadoxetic acid-enhanced MR imaging. Eur Radiol 25(1):211–220CrossRefPubMed

26.

Hope TA, Fowler KJ, Sirlin CB, et al. (2015) Hepatobiliary agents and their role in LI-RADS. Abdom Imaging 40(3):613–625CrossRefPubMed

Titel: MR-imaging features of hepatocellular carcinoma capsule appearance in cirrhotic liver: comparison of gadoxetic acid and gadobenate dimeglumine
verfasst von: Marco Dioguardi Burgio
Dario Picone
Giuseppe Cabibbo
Massimo Midiri
Roberto Lagalla
Giuseppe Brancatelli
Publikationsdatum: 06.04.2016
Verlag: Springer US
Erschienen in: Abdominal Radiology / Ausgabe 8/2016
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI: https://doi.org/10.1007/s00261-016-0726-7

Neu im Fachgebiet Radiologie

18.04.2024 | Pädiatrische Notfallmedizin | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

MR-imaging features of hepatocellular carcinoma capsule appearance in cirrhotic liver: comparison of gadoxetic acid and gadobenate dimeglumine

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Update Radiologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2016

Increase in post-therapy tumor calcification on CT scan is not an indicator of response to therapy in low-grade serous ovarian cancer

The “manta ray” pelvis

Emerging stool-based and blood-based non-invasive DNA tests for colorectal cancer screening: the importance of cancer prevention in addition to cancer detection

Radiology of epiploic appendages: acute appendagitis, post-infarcted appendages, and imaging natural history

Reduction of peristalsis-related gastrointestinal streak artifacts with dual-energy CT: a patient and phantom study

The role of diffusion-weighted MRI in assessment of inflammatory bowel disease

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Update Radiologie